Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
1,584,707
-
Total 13F shares
-
202,365
-
Share change
-
-26,944
-
Total reported value
-
$200,198
-
Price per share
-
$0.99
-
Number of holders
-
14
-
Value change
-
-$40,810
-
Number of buys
-
4
-
Number of sells
-
5
Institutional Holders of Cyclacel Pharmaceuticals, Inc. - Common Stock, $0.001 par value (CYCC) as of Q3 2024
As of 30 Sep 2024,
Cyclacel Pharmaceuticals, Inc. - Common Stock, $0.001 par value (CYCC) was held by
14 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
202,365 shares.
The largest 10 holders included
ARMISTICE CAPITAL, LLC, Point72 Asset Management, L.P., ACADIAN ASSET MANAGEMENT LLC, UBS Group AG, GEODE CAPITAL MANAGEMENT, LLC, Tower Research Capital LLC (TRC), McIlrath & Eck, LLC, Activest Wealth Management, OSAIC HOLDINGS, INC., and MORGAN STANLEY.
This page lists
14
institutional shareholders reporting positions in this security
for the Q3 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.